FDA lifts rosiglitazone prescribing restrictions
Read the full story on MD Consult:
FDA lifts rosiglitazone prescribing restrictions (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - December 4, 2013 Category: Journals (General) Source Type: news
FDA lifts constraints on Glaxo diabetes drug Avandia (Reuters, 25 November 2013)
The US Food and Drug Administration (FDA) has announced it will lift certain restrictions placed on the diabetes drug Avandia (rosiglitazone).
Full article
FDA announcement (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 27, 2013 Category: Endocrinology Source Type: news
Avandia Decision a Moot Point for Prescribers?
(MedPage Today) -- It's unlikely that the FDA's decision to loosen some of the restrictions on the type 2 diabetes drug rosiglitazone (Avandia) will have any impact on prescribing in the U.S., according to several experts contacted by MedPage Today. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 26, 2013 Category: American Health Source Type: news
Few See Renewed Role for Rosiglitazone in DiabetesFew See Renewed Role for Rosiglitazone in Diabetes
The question on everyone's lips now is what will happen to rosiglitazone. Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
FDA to Lift Restrictions on Diabetes Drug Avandia
Title: FDA to Lift Restrictions on Diabetes Drug AvandiaCategory: Health NewsCreated: 11/25/2013 5:36:00 PMLast Editorial Review: 11/26/2013 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 26, 2013 Category: Endocrinology Source Type: news
With No Increase in MI Risk Found, Some Avandia Restrictions Lifted (FREE)
By Amy Orciari Herman
Certain restrictions on the diabetes drug rosiglitazone (Avandia) are being removed because a new analysis from the RECORD trial has found no increase in myocardial infarction risk — a risk first suggested by a 2007 meta-analysis.In 2010, the FDA ruled … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 26, 2013 Category: Primary Care Source Type: news
F.D.A. Lifts Some Restrictions on Avandia
Doctors said the move was unlikely to breathe new life into the diabetes drug, which has been largely discredited in the United States. (Source: NYT)
Source: NYT - November 26, 2013 Category: American Health Authors: By SABRINA TAVERNISE Tags: Drugs (Pharmaceuticals) Avandia (Drug) Food and Drug Administration Diabetes GlaxoSmithKline PLC GSK NYSE Source Type: news
FDA Removes Marketing Limits on Diabetes Drug Avandia
The FDA, in a U-turn from its position three years ago, removed the restrictions it imposed on the sale of GlaxoSmithKline's diabetes drug Avandia. (Source: WSJ.com: Health)
Source: WSJ.com: Health - November 26, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
FDA Removes Restrictions On Avandia
In a remarkable climax to a long-running drama, the FDA today lifted major restrictions on rosiglitazone (Avandia, GlaxoSmithKline). The drug has been the subject of intense criticism and controversy since the 2007 publication of the famous Nissen meta-analsysis that first raised the possibility that the blockbuster diabetes drug might increase the risk of heart attack and cardiovascular death. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
FDA Lifts Avandia Prescribing RestrictionsFDA Lifts Avandia Prescribing Restrictions
After a 2-day advisory committee meeting last June, the FDA has decided that current data do not suggest that the drug poses an increased cardiovascular risk. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
GSK Responds to FDA Decision on Avandia (rosiglitazone)
GSK plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee review in June 2013. (Source: GSK news)
Source: GSK news - November 25, 2013 Category: Pharmaceuticals Source Type: news
FDA to Lift Restrictions on Diabetes Drug Avandia
Not all experts are happy with granting wider access to the troubled medication, however (Source: WebMD Health)
Source: WebMD Health - November 25, 2013 Category: Consumer Health News Source Type: news
FDA loosens restrictions on diabetes drug Avandia
The Food and Drug Administration said Monday that it was loosening restrictions on the controversial diabetes drug Avandia "to reflect new information regarding the cardiovascular risk." (Source: CNN.com - Health)
Source: CNN.com - Health - November 25, 2013 Category: Consumer Health News Source Type: news
FDA Opens Door to Wider Avandia Prescribing
(MedPage Today) -- The FDA has loosened restrictions on the diabetes drug rosiglitazone (Avandia) -- under fire since 2007 because of potential cardiovascular risks -- and will allow drugmaker GlaxoSmithKline to drop a postmarketing study of the drug. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 25, 2013 Category: Cardiology Source Type: news
Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - Removal of Some Prescribing and Dispensing Restrictions
Health care professionals, pharmacies, and patients will no longer be required to enroll in the rosiglitazone REMS program to be able to prescribe, dispense, or receive rosiglitazone medicines. (Source: FDA MedWatch)
Source: FDA MedWatch - November 25, 2013 Category: American Health Source Type: news
